Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert.

@article{Paulson2014ProgesteronePA,
  title={Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert.},
  author={Richard J. Paulson and Michael G. Collins and Vladimir I. Yankov},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2014},
  volume={99 11},
  pages={
          4241-9
        }
}
CONTEXT Progesterone vaginal insert (PVI), an effervescent delivery system, dissolves rapidly, is absorbed through the vaginal epithelium, and achieves higher endometrial tissue concentrations than those achieved with progesterone in oil (PIO) given im. OBJECTIVE Our objective was to examine the pharmacokinetics and pharmacodynamics of PVI compared with PIO. DESIGN, SETTING, AND PARTICIPANTS Fifty-eight healthy premenopausal women were randomized to 50, 100, or 200 mg PVI once daily; 100 or… Expand
Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally
TLDR
CYP2C19 may condition progesterone disposition and that it may be more relevant than CYP2C9, and it is suggested that CYP1C9 may not be as relevant as it is thought to be in the present study. Expand
Pharmacokinetics of Vaginal Progesterone in Pregnancy.
TLDR
Unlike in non-pregnant individuals, administration of vaginal progesterone in pregnant individuals only minimally impacts systemic exposure, and Serum progestersone is unlikely to be a good candidate for establishing pharmacokinetics or dosing of vaginal Progesterone in pregnancy for preterm birth prevention. Expand
A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth
TLDR
There did not appear to be a difference between vaginal progesterone and 17-OHPC when used for the prevention of a recurrent PTB, or its optimal formulation and dose. Expand
Evaluation of progestogen supplementation for luteal phase support in fresh in vitro fertilization cycles.
TLDR
This broad-ranging meta-analysis highlights the need to reevaluate current clinical practice and concludes that the use of progestogens in fresh IVF cycles is substantially beneficial to clinical pregnancy. Expand
Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study.
TLDR
The findings study suggest a role for oral dydrogesterone in addition to vaginal progesterone as luteal phase support as well as a systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. Expand
Effect of Individualized Progesterone Supplementation for Luteal Support in Frozen-Thawed Cycles on Pregnancy Outcomes
OBJECTIVE: In frozen-thawed embryo transfer cycles, preparing a synchronous endometrium for the embryo is essential. The aim of this study is to provide individualized luteal support in hormonallyExpand
Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy
TLDR
To measure pharmacokinetics of hydroxyprogesterone caproate and its major metabolites throughout pregnancy, blood drawn for 7 consecutive days at one of three times was used to estimate terminal half-life of OHPC and di-hydroxylated metabolite levels were significantly lower than mono-hydoxylated metabolites. Expand
17-α Hydroxyprogesterone Nanoemulsifying Preconcentrate-Loaded Vaginal Tablet: A Novel Non-Invasive Approach for the Prevention of Preterm Birth
TLDR
There were significant differences in rates of PTB and average time to delivery between control and vaginal 17P-treated groups in LPS-stimulated timed pregnant E15.5 mice. Expand
Do early luteal serum progesterone levels predict the reproductive outcomes in IVF with oral dydrogesterone for luteal phase support?
TLDR
A positive association between early P4 levels and reproductive outcomes in IVF using oral dydrogesterone for luteal support is suggested, suggesting that extrapolation is impractical. Expand
Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction.
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards theExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 38 REFERENCES
Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects.
TLDR
Endometrin vaginal inserts reached higher Cmax, produced greater systemic exposure (area under the curve 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than the comparator. Expand
Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study.
TLDR
Vaginal micronized P enhances P delivery to the uterus compared with a standard IM regimen and results in a synchronous secretory endometrial histology in agonadal women preparing for embryo donation. Expand
Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet.
TLDR
Natural progesterone given as a vaginal tablet is well tolerated, safe and an easily administered treatment and even in a non-oestrogenized vagina the absorption was efficient and the 100 mg dosage resulted in adequate serum progestersone concentrations. Expand
Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone.
TLDR
The data indicate that vaginal absorption of progesterone is efficient, and the lack of difference in the area under the curve for both doses suggests that the vaginal mucosa or the total surface area of the vagina may limit the absorption ofprogesterone from the vagina. Expand
Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial.
TLDR
Progesterone vaginal gel can be successfully used as an alternative to intramuscular progesterone for luteal support in IVF and one daily dose appears sufficient to induce clinical pregnancies and live births at a rate comparable to intramsuscular supplementation. Expand
Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles.
TLDR
Crinone 8% administered once daily appears to produce the same endometrial development and pregnancy rates as IM progesterone in women who require complete progester one replacement, and it does not cause early bleeding. Expand
Direct Transport of Progesterone From Vagina to Uterus
TLDR
The authors' findings in endometrial tissue specimens from hysterectomies excluded the possibility of contamination by progesterone that remained in the vagina, andRatios ofendometrial to serum progester one concentrations were higher after vaginal administration of progestersone than after IM injections. Expand
A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone.
TLDR
Meta-analysis of progesterone luteal support in IVF cycles using odds ratios (OR) and 95% confidence intervals (CI) showed a comparable effect between vaginal P as an oil-in-capsule or as a bioadhesive gel and IM P administration on the endpoints of clinical pregnancy and ongoing pregnancy. Expand
Comparison between different routes of progesterone administration as luteal phase support in infertility treatments.
TLDR
Vaginally administered progesterone results in adequate secretory endometrial transformation, despite serum progester one values lower than those observed after i.m. administration, which is indicative of the first uterine pass effect and therefore of a better bioavailability of progestersone in the uterus, with minimal systematic undesirable effects. Expand
Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles.
TLDR
The results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, but differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study. Expand
...
1
2
3
4
...